DaShenLin Pharmaceutical Group financials at a glance

+ Portfolio

The revenue of DaShenLin Pharmaceutical Group is reported as 24.53139 billion Yuan Renminbi in the fiscal year 2023. The earnings were 1 Yuan Renminbi per share in 2023, which was 12.36 higher than 2022. And about 1.37721 billion Yuan Renminbi are reported as free cash flow in the financials of DaShenLin Pharmaceutical Group 2023. Dividends of 0.31 Yuan Renminbi per share were paid to shareholders of DaShenLin Pharmaceutical Group stock SHSE:603233 in fiscal 2023.

¥24.53B

Revenue

¥1.00

Earnings Per Share

35.90%

Gross Margin %

¥708.00M

Free Cash Flow

Revenue

24,531.39

Earnings Per Share

1.00

Gross Margin %

35.90

Free Cash Flow

708.00

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018
Rev.	Revenue	N/A	¥24.53B	¥21.25B	¥16.76B	¥14.58B	¥11.14B	¥8.86B
GM %	Gross Margin %	36.62%	35.90%	37.76%	38.03%	38.33%	39.39%	41.57%
OM	Operating Margin	7.96%	7.80%	7.47%	6.57%	9.33%	8.22%	8.06%
EPS	Earnings Per Share	¥1.13	¥1.00	¥0.89	¥0.63	¥0.90	¥0.64	¥0.47
Div.	Dividends	N/A	¥0.31	¥0.50	¥0.35	¥0.46	¥0.29	¥0.22
PR %	Payout Ratio %	0	31.00%	56.18%	55.56%	51.11%	45.31%	46.81%
Sha.	Shares	N/AM	1,109.63M	1,138.94M	1,138.95M	1,138.1M	1,118.79M	1,078.3M
OCF	Operating Cash Flow	N/A	¥3.17B	¥3.76B	¥1.55B	¥1.95B	¥1.71B	¥873.64M
FCF	Free Cash Flow	N/A	¥708.00M	¥2.76B	¥281.66M	¥1.17B	¥1.21B	¥319.25M
FCFS	Free Cash Flow Per Share	¥1.80	¥1.22	¥2.39	¥0.27	¥1.48	¥1.92	¥0.51

DaShenLin Pharmaceutical Group financials at a glance

Financials

Discover